Company research
Alkermes plc.
CIK 1520262Updated Sep 27, 2026
SecurityALKS · NASDAQ · equity
Name history
ANTLER SCIENCE TWO PLC · through Aug 5, 2011Antler Science Two Ltd · through Aug 2, 2011
ALKS price & chart
Loading TradingView…
NASDAQ:ALKS on TradingView ↗About the company
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
In the news
Alkermes plc Reports Third Quarter 2025 Financial Results News provided by Alkermes plc Oct 28, 2025, 07:00 ET Share this article Share to X Share this article Share to X — Third Quarter Revenues of $394.2 Million — — GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.4 ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
144 filing
144 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,486,993,000Source | 2,055,567,000Source | 2,136,223,000Source | 1,963,978,000Source |
| Property, Plant and Equipment, NetUSD | 221,722,000Source | 227,564,000Source | 226,943,000Source | 325,361,000Source |
| GoodwillUSD | 83,027,000Source | 83,027,000Source | 83,027,000Source | 92,873,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 388,570,000Source | 291,146,000Source | 457,469,000Source | 292,473,000Source |
| Inventory, NetUSD | 196,625,000Source | 182,887,000Source | 186,406,000Source | 181,418,000Source |
| Assets, CurrentUSD | 1,929,161,000Source | 1,415,355,000Source | 1,485,506,000Source | 1,130,306,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 79,090,000Source | 91,282,000Source | 98,166,000Source | 43,527,000Source |
| Operating Lease, Right-of-Use AssetUSD | 77,209,000Source | 84,245,000Source | 91,460,000Source | 115,855,000Source |
| Other Assets, NoncurrentUSD | 49,099,000Source | 16,503,000Source | 11,521,000Source | 14,691,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 667,698,000Source | 590,590,000Source | 933,537,000Source | 920,225,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,810,000Source | 1,767,000Source | 1,726,000Source | 1,690,000Source |
| Retained Earnings (Accumulated Deficit)USD | -734,794,000Source | -976,458,000Source | -1,343,528,000Source | -1,699,285,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,100,000Source | -1,967,000Source | -3,110,000Source | -10,889,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,819,295,000Source | 1,464,977,000Source | 1,202,686,000Source | 1,043,753,000Source |
| Additional Paid in Capital, Common StockUSD | 3,004,666,000Source | 2,860,890,000Source | 2,736,934,000Source | 2,913,099,000Source |
| Liabilities and EquityUSD | 2,486,993,000Source | 2,055,567,000Source | 2,136,223,000Source | 1,963,978,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 543,437,000Source | 465,199,000Source | 520,220,000Source | 497,742,000Source |
| Operating Lease, Liability, CurrentUSD | 6,746,000Source | 6,166,000Source | 5,746,000Source | 15,722,000Source |
| Accounts Payable, CurrentUSD | 107,950,000Source | 45,630,000Source | 65,649,000Source | 32,843,000Source |
| Operating Lease, Liability, NoncurrentUSD | 63,253,000Source | 69,372,000Source | 75,709,000Source | 89,829,000Source |
| Other Liabilities, NoncurrentUSD | 61,008,000Source | 56,019,000Source | 49,878,000Source | 42,384,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | — | — | — | 47,776,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 3,000,000Source | 3,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 287,730,000Source | 290,270,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 241,664,000Source | 367,070,000Source | 355,757,000Source | -158,267,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 27,165,000Source | 28,533,000Source | 74,927,000Source | 77,862,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 98,716,000Source | 96,637,000Source | 100,905,000Source | 94,254,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 14,061,000Source | -3,091,000Source | 2,712,000Source | 31,021,000Source |
| Deferred Income Tax Expense (Benefit)USD | 28,774,000Source | 40,522,000Source | -99,902,000Source | -32,795,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 520,754,000Source | 439,124,000Source | 401,353,000Source | 21,044,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 295,497,000Source | -111,308,000Source | 53,357,000Source | -64,541,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 40,420,000Source | 33,484,000Source | 48,048,000Source | 38,255,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 31,032,000Source | 29,637,000Source | 28,474,000Source | 18,204,000Source |
| Payments for Repurchase of Common StockUSD | — | 200,282,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 12,379,000Source | -494,139,000Source | -289,714,000Source | -1,574,000Source |
| Repayments of Long-term DebtUSD | — | 2,250,000Source | 3,000,000Source | 3,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 828,630,000Source | -166,323,000Source | 164,996,000Source | -45,071,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,119,776,000Source | 291,146,000Source | 457,469,000Source | 292,473,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 23,010,000Source | 22,748,000Source | 13,563,000Source |
| Income Taxes Paid, NetUSD | 5,237,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 98,716,000Source | 96,637,000Source | 100,905,000Source | 94,254,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | 500,000Source |
| Amortization of Intangible AssetsUSD | — | 1,101,000Source | 35,689,000Source | 36,363,000Source |
| DepreciationUSD | 31,100,000Source | 27,400,000Source | 25,700,000Source | 41,700,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | 1,500,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,000,000Source | -800,000Source | -500,000Source | 700,000Source |
| General and Administrative ExpenseUSD | 221,511,000Source | 199,024,000Source | — | — |
| GoodwillUSD | 83,027,000Source | 83,027,000Source | 83,027,000Source | 92,873,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 241,664,000Source | 372,138,000Source | 519,157,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | -5,068,000Source | -163,400,000Source | — |
| Income Tax Expense (Benefit)USD | 49,786,000Source | 71,612,000Source | -97,638,000Source | -9,037,000Source |
| InterestExpenseNonoperatingUSD | 12,277,000Source | 22,578,000Source | — | — |
| Investment Income, InterestUSD | 45,304,000Source | 42,450,000Source | 30,854,000Source | 7,629,000Source |
| Net Income (Loss) Attributable to ParentUSD | 241,664,000Source | 367,070,000Source | 355,757,000Source | -158,267,000Source |
| Nonoperating Income (Expense)USD | 37,494,000Source | 23,114,000Source | 7,397,000Source | -25,039,000Source |
| Operating Lease, ExpenseUSD | 7,500,000Source | 7,200,000Source | 10,200,000Source | 16,600,000Source |
| Other Nonoperating Income (Expense)USD | 4,467,000Source | 3,242,000Source | -425,000Source | 2,122,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,475,899,000Source | 1,557,632,000Source | 1,663,405,000Source | 1,111,795,000Source |
| Cost of RevenueUSD | 196,457,000Source | 245,331,000Source | 253,037,000Source | 218,108,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 701,522,000Source | 645,238,000Source | 689,751,000Source | 605,747,000Source |
| Operating Income (Loss)USD | 253,956,000Source | 420,636,000Source | 414,122,000Source | -142,265,000Source |
| Other Nonoperating Income (Expense)USD | 4,467,000Source | 3,242,000Source | -425,000Source | 2,122,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 291,450,000Source | 443,750,000Source | 421,519,000Source | -167,304,000Source |
| Income Tax Expense (Benefit)USD | 49,786,000Source | 71,612,000Source | -97,638,000Source | -9,037,000Source |
| Net Income (Loss) Attributable to ParentUSD | 241,664,000Source | 367,070,000Source | 355,757,000Source | -158,267,000Source |
| Earnings Per Share, BasicUSD per share | 1.47Source | 2.22Source | 2.14Source | -0.97Source |
| Earnings Per Share, DilutedUSD per share | 1.43Source | 2.17Source | 2.1Source | -0.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 164,703,000Source | 165,392,000Source | 166,223,000Source | 163,541,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 168,743,000Source | 169,198,000Source | 169,730,000Source | 163,541,000Source |
| Interest Expense (non-operating)USD | 12,277,000Source | 22,578,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 1,101,000Source | 35,689,000Source | 36,363,000Source |
| Costs and ExpensesUSD | 1,221,943,000Source | 1,136,996,000Source | 1,249,283,000Source | 1,254,060,000Source |
| Current Income Tax Expense (Benefit)USD | 21,012,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 1,000,000Source | -800,000Source | -500,000Source | 700,000Source |
| General and Administrative ExpenseUSD | 221,511,000Source | 199,024,000Source | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 241,664,000Source | 372,138,000Source | 519,157,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | 1.47Source | 2.25Source | 3.12Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | 1.43Source | 2.2Source | 3.06Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | -5,068,000Source | -163,400,000Source | — |
| Interest ExpenseUSD | — | — | 23,032,000Source | 13,040,000Source |
| Investment Income, InterestUSD | 45,304,000Source | 42,450,000Source | 30,854,000Source | 7,629,000Source |
| Nonoperating Income (Expense)USD | 37,494,000Source | 23,114,000Source | 7,397,000Source | -25,039,000Source |
| Operating Lease, ExpenseUSD | 7,500,000Source | 7,200,000Source | 10,200,000Source | 16,600,000Source |
| Research and Development ExpenseUSD | 323,964,000Source | 245,326,000Source | 270,806,000Source | 393,842,000Source |
| Selling and Marketing ExpenseUSD | 480,011,000Source | 446,214,000Source | — | — |
Filing attachments
alks-ex99_1.htm · 8-K · 2026-09-21
Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults - - ALKS 7290 Was Generally Well Tolerated at All Doses Te…
Read attachment ↗alks-ex99_1.htm · 8-K · 2026-09-16
EX-99 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors DUBLIN, Sept. 16, 2026 - Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board di…
Read attachment ↗alks-ex99_1.htm · 8-K · 2026-07-28
EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results - Second Quarter Revenues of $496.0 Million - - GAAP Net Income of $0.5 Million and Adjusted EBITDA of $139.2 Million - - Blair Jackson to Assume Chief Executive Officer Role on August 1, 2026; Richard Pops to Continue as Chairman of the Board of…
Read attachment ↗alks-ex99_2.htm · 8-K · 2026-07-28
EX-99.2 3 alks-ex99_2.htm EX-99.2 Second Quarter 2026 Financial Results & Business Update July 28, 2026 Exhibit 99.2 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc’s (the “Company”) expectations with respect to its current and future f…
Read attachment ↗alks-ex99_1.htm · 8-K · 2026-06-15
EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs, +1 781 609 6377 For Media: Gretchen Murphy,+1 781 609 6419 Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe DUBLIN, June 15, 2026 -- Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT…
Read attachment ↗alks-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Announces Positive Topline Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia - LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compa…
Read attachment ↗